Ειδήσεις: GENE THERAPY | PXAI

Version	Description	Date
8.42	[ADDED SOURCE REGISTRY LIST VIEW]	04/03/2026 16:19
8.41	[LOCALIZED INDEX.PHP MENU AND MODALS TO US ENGLISH]	04/03/2026 16:11
8.40	[TRANSLATED FRONTEND TO US ENGLISH]	04/03/2026 16:10
8.41	[RESTORED DETAILED SOURCES VIEW (ARTICLES + EVENTS) IN US ENGLISH]	04/03/2026 15:50
8.41	[RESTORED DETAILED SOURCES VIEW (ARTICLES + EVENTS) IN US ENGLISH]	04/03/2026 15:46
8.40	[REVERTED TO STANDARD TABLE LAYOUT (US ENGLISH)]	04/03/2026 15:40
8.39	[FIXED DB CONNECTION SCOPE IN SOURCES LOGIC]	04/03/2026 15:38
8.38	[TRANSLATED SOURCES VIEW TO US ENGLISH]	04/03/2026 15:01
8.37	[FULL FRONTEND TRANSLATION (MENU, FEED, COMMENTS, TTS) TO US ENGLISH.]	04/03/2026 14:58
8.67	[MANUAL OVERRIDE OF GREEK MENU ITEMS]	04/03/2026 13:36
8.66	[NGINX OPTIMIZED MENU FIX]	04/03/2026 13:33
8.65	[FIXED GREEK MENU ITEMS]	04/03/2026 13:32
8.60	[MENU & UI LOCALIZATION TO US ENGLISH]	04/03/2026 13:30
8.50	[FULL TRANSLATION TO US ENGLISH]	04/03/2026 13:27
9.75	[INJECTED EVENT FUSION_SUMMARY INTO FEED LOOPS TO DISPLAY AI TAGS CORRECTLY]	26/02/2026 14:44

24/03 14:51 investing.com

Ocugen stock falls 5% despite positive gene therapy trial data

Ocugen gene therapy biotech stock decline clinical trial investor sentiment

23/03 21:08 cryptobriefing.com

David Sinclair: Aging can be reversed, gene therapy is key to rejuvenation, and we may live into the twenty-second century | The Diary of a CEO

David Sinclair gene therapy aging reversal longevity blindness trials human health

22/03 14:30 newsweek.com

Biotech Stocks and Longevity Investing: Trends To Track

biotech longevity gene therapy digital health investing market trends

19/03 07:02 defenseworld.net

Abeona Therapeutics Q4 Earnings Call Highlights

Abeona ZEVASKYN gene therapy RDEB commercial launch manufacturing capacity

18/03 17:03 statnews.com

STAT+: A Huntington’s researcher on the UniQure-FDA fray

UniQure Huntington's disease FDA rejection gene therapy Ed Wild regulatory hurdles

18/03 07:06 defenseworld.net

4D Molecular Therapeutics Highlights 4D-150 Phase III Momentum, DME Plans, Cash Runway at Leerink Conference

4D Molecular Therapeutics 4D‑150 Phase III wet AMD DME gene therapy

17/03 09:04 defenseworld.net

enGene Highlights 2026 Data Catalysts, BLA Plans for Bladder Cancer Gene Therapy at Barclays Conference

enGene DDX platform non‑viral gene therapy detalimogene NMIBC pivotal trial

17/03 09:04 defenseworld.net

enGene Highlights 2026 Data Catalysts, BLA Plans for Bladder Cancer Gene Therapy at Barclays Conference

enGene DDX platform non‑viral gene therapy detalimogene NMIBC pivotal trial

Loading...